ArticleCell biochemistry and biophysics2025
A Risk Prognostic Signature Basing on Cuproptosis-related Ferroptosis and Immune Genes for Esophageal Squamous Cell Carcinoma Patients.
Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Cuproptosis-Associated AL139023.1/miR-139-5p/ELOVL5 ceRNA Axis Regulates Proliferation, Migration, and Cell Cycle in Esophageal Squamous Cell Carcinoma.Cancer management and research · 2026Article
- Targeting ferroptosis and cuproptosis in gastrointestinal cancers: molecular mechanisms, metabolic vulnerabilities, and therapeutic interventions.Molecular biomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal cancer (EC) is a highly aggressive malignancy, with esophageal squamous cell carcinoma (ESCC) accounting for the majority of cases worldwide. Despite advances in treatment, the prognosis for ESCC remains poor, underscoring the urgent need for reliable prognostic biomarkers to guide clinical decision-making. In this study, we constructed a novel prognostic model by integrating cuproptosis-related genes with ferroptosis and immune-associated genes-three critical pathways implicated in tumor progression and immune modulation. Gene expression and clinical data from ESCC patients were obtained from the GSE53625 and TCGA-ESCC cohorts. Ferroptosis- and immune-related genes (FIRGs) were sourced from FerrDb and ImmPort databases, and their association with cuproptosis-related genes was determined via Pearson correlation, yielding a set of cuproptosis-associated FIRGs (FI-CRGs). Thirteen prognostically relevant FI-CRGs were identified through Cox regression analysis and used to develop a risk score model (FI-CRS). The FI-CRS demonstrated robust predictive performance in both the training cohort (GSE53625, n = 179) and the independent validation cohort (TCGA-ESCC, n = 81), where high-risk patients exhibited significantly reduced overall survival (p < 0.05). Functional enrichment analyses (GO and KEGG) revealed strong associations between high FI-CRS and immunoregulatory pathways. Further investigation showed notable differences in immune cell infiltration and drug sensitivity between risk groups. Additionally, a prognostic nomogram incorporating clinical features (age, gender, TNM staging, and FI-CRS) was established to enhance individualized survival prediction. Altogether, this study presents a novel, integrative in silico framework that not only offers promising biomarkers for prognosis but also provides mechanistic insights into ESCC biology, potentially informing future therapeutic strategies.
Indexed as
Identifiers
40504362What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.